UCB SA (OTCMKTS:UCBJY – Get Free Report)’s share price reached a new 52-week high on Wednesday . The company traded as high as $100.43 and last traded at $100.18, with a volume of 7440 shares trading hands. The stock had previously closed at $98.57.
UCB Price Performance
The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78. The company has a 50-day simple moving average of $96.52 and a 200-day simple moving average of $89.85.
About UCB
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Further Reading
- Five stocks we like better than UCB
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Moderna Shares Spike on H5N1 News—What’s Next for Investors?
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Nebius Group (NBIS): A Small-Cap Backed by NVIDIA
- Insider Trading – What You Need to Know
- Natural Gas Demand to Surge: Top 3 Stocks and ETFs to Consider
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
